A systematic review and meta-analysis conducted by researchers at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, suggests that angiotensin-receptor blockers (ARBs) are associated with "a modestly increased risk" of developing cancer (RR increase of 8%, P=.016).
A systematic review and meta-analysis conducted by researchers at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, suggests that angiotensin-receptor blockers (ARBs) are associated with "a modestly increased risk" of developing cancer (RR increase of 8%, P=.016).
The meta-analysis which, systematically pooled available literature through November 2009, recently was published in the July 2010 Lancet Oncology.
While not detected in early-stage development, results of clinical evaluations (including a prior meta-analysis published in 2008 by researchers at the University of Connecticut) have suggested that ARBs may have a propensity to increase cancer risk since angiotensin II type-1 and type-2 receptors (AT1R and AT2R) play an important role in cellular proliferation, angiogenesis, and consequently tumor progression.
For this most recent meta-analysis, investigators conducted a systematic literature search of MEDLINE, SCOPUS, CENTRAL, the Cochrane Database of Systematic Reviews, and FDA website in order to identify randomized trials evaluating an ARB, with a follow-up of at least 1 year; and that enrolled at least 100 patients.
The search identified 5 trials (n=61,590 patients) reporting data on the development of new cancer. Of note, nearly 86% of these patients received telmisartan. Upon meta-analysis, patients randomly assigned to receive an ARB had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2% vs 6.0%, RR, 1.08, 95% CI, 1.01–1.15; P=.016). Despite more new cases of cancer in the patients treated with an ARB, no statistically significant difference in cancer deaths was seen (1.8% vs 1.6%, RR, 1.07, 0.97–1.18; P=.183).
Investigators stated, "The increased risk of new cancer occurrence is modest but significant. However, the clinical significance of this potential excess cancer risk is unknown."
The paper concluded by cautioning readers that due to limitations in available data, it was impossible to draw conclusions about the exact risk of cancer associated with each individual ARB. Furthermore it suggested that further investigation is warranted.
This study was unfunded.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.